Joseph Zack joins Metabolon
This article was originally published in Clinica
Metabolomics biomarker company Metabolon has appointed Joseph Zack senior vice-president of diagnostics. Mr Zack has over 30 years of experience in the biopharmaceutical and diagnostics industry, and was previously vice-president of marketing and sales for Orasure Technologies, where he expanded the firm's diagnostic and device business. He has also worked for OraPharma, Advanced Tissue Sciences and Ciba-Geigy Pharmaceuticals (now Novartis). Metabolon has a patented biochemical platform which analyses biological samples to discover markers and pathways associated with diseases and drug action. The Research Triangle Park, North Carolina company is using this metabolomics-driven approach to develop diagnostics for diabetes, prostate cancer and amyotrophic lateral sclerosis.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.